Physician profile
Gerald M Aronoff
NPI 1144277930
$16,795.66
in general payments reported to CMS, 2019-2025
40 companies · $1,158 in 2025
The $1,158 reported for 2025 was more than what a typical Pain Medicine provider received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $1,111 · 2021: $969 · 2022: $963 · 2023: $1,336 · 2024: $1,197 · 2025: $1,158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,691.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,691.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $7,738.50 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,919.84 | 2019-2025 | Relistor |
| Collegium Pharmaceutical, INC. | $1,278.13 | 2019-2025 | Xtampza, Belbuca |
| Abbvie INC. | $1,049.21 | 2023-2025 | Ubrelvy, Qulipta |
| Arbor Pharmaceuticals, INC. | $604.70 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $473.08 | 2023-2024 | Quviviq |
| Scilex Pharmaceuticals INC. | $404.52 | 2019-2025 | Ztlido |
| Biodelivery Sciences International, INC. | $396.67 | 2019-2021 | |
| Azurity Pharmaceuticals, INC. | $367.28 | 2023-2025 | Horizant, Horizant |
| Sentynl Therapeutics, INC. | $329.69 | 2019 | |
| Indivior INC. | $315.39 | 2019-2021 | |
| Pfizer INC. | $247.58 | 2019-2025 | |
| Forte Bio-Pharma LLC | $225.14 | 2019-2025 | Prolate, Tanlor, Nalocet |
| Averitas Pharma INC. | $169.45 | 2023 | |
| Assertio Therapeutics, INC. | $139.46 | 2019 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Aronoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.